# A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Source: https://onco.cc/trials/nct07186842/  
OnCo record `nct07186842` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BNT329 in advanced solid tumours, run by BioNTech SE, now recruiting.

## Summary

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 is a phase 1/2 interventional study registered as NCT07186842 by BioNTech SE, with 245 participants planned, started 2025-11-18 and due to reach its primary completion in 2030-05. Interventions recorded: BNT329 and CA19-9-targeting monoclonal antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07186842
- Phase: 1/2
- Setting: First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9
- Sponsor: BioNTech SE
- Enrolled: 245

## Sources

- ClinicalTrials.gov NCT07186842: https://clinicaltrials.gov/study/NCT07186842

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct07186842.json